CEP55 Inhibitor: Extensive Computational Approach Defining a New Target of Cell Cycle Machinery Agent
Beni Lestari1, Rohmad Yudi Utomo1,2
1Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281, Indonesia.
Abstract:
Centrosomal protein 55 (CEP55) is a pivotal protein for cytokinesis during cell division. This study aimed to provide a comprehensive information about the CEP55 gene, including its expression pattern in several cancer types, conduct functional domain analysis across species, and perform a computational approach for potential inhibitors of CEP55. The expression levels of CEP55 in different cancers were analyzed using the Oncomine and TCGA databases. Evolutionary analysis of the CEP55 gene in various species was performed using MEGA-X software. Molecular docking analysis was used to screen the binding affinity of several natural products on CEP55-ALIX binding interaction. High CEP55 expression was observed in 16 datasets of different cancer types. The high expression of the CEP55 protein was associated with worse outcomes in cancer treatments. Phylogenetic and evolutionary analyses revealed that the amino acid residues essential for CEP55 binding and localization were mostly conserved across vertebrates. Seventeen plant-based compounds were docked against the CEP55 protein to determine their binding affinities and illustrated specific sites of interaction for predicting novel protein-drug interactions. Flavanol compounds epigallocatechin gallate and catechin possessed superior binding affinity to all other compounds owing to the substitution of gallic ester or hydroxyl groups on the C3 position. This study provides comprehensive information about the CEP55 gene and insights for designing potent inhibitors against CEP55 signaling.
Insights
Centrosomal protein 55 (CEP55) is highly expressed in many cancers, correlating with poor outcomes. This study analyzed CEP55
Area of Science:
- Molecular Biology
- Genomics
- Biochemistry
Background:
- Centrosomal protein 55 (CEP55) plays a critical role in cytokinesis, the final stage of cell division.
- Aberrant CEP55 expression is implicated in various human cancers, suggesting its potential as a therapeutic target.
Purpose of the Study:
- To comprehensively analyze the CEP55 gene, including its expression patterns in diverse cancer types.
- To perform functional domain analysis across species and identify potential CEP55 inhibitors using computational methods.
Main Methods:
- Gene expression analysis utilizing Oncomine and TCGA databases.
- Phylogenetic and evolutionary analysis of the CEP55 gene using MEGA-X software.
- Molecular docking simulations to assess the binding affinity of natural compounds to CEP55.
Main Results:
- Elevated CEP55 expression was detected in 16 cancer datasets, associated with worse patient prognoses.
- Conserved amino acid residues crucial for CEP55 function were identified across vertebrate species.
- Flavanol compounds, specifically epigallocatechin gallate and catechin, demonstrated high binding affinity to CEP55.
Conclusions:
- CEP55 is a significant biomarker for cancer progression and a potential therapeutic target.
- The conserved nature of CEP55 suggests conserved functions across species.
- Natural compounds like epigallocatechin gallate and catechin show promise as CEP55 inhibitors for cancer therapy.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11:49Author Spotlight: Establishing CENP-E Knockout HeLa Cells – A Novel Approach to Study Kinesin-7 CENP-E Biology and its Inhibitors
Published on: June 23, 2023
Related Concept Videos
Inhibition of Cdk Activity
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
Positive Regulator Molecules
Negative Regulator Molecules
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Anaphase Promoting Complex
